Showing 2971-2980 of 5646 results for "".
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the 
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Ocumension Therapeutics Secures Deal with Alcon to Expand Dry Eye Treatment Portfolio in Chinahttps://modernod.com/news/ocumension-therapeutics-secures-deal-with-alcon-to-expand-dry-eye-treatment-portfolio-in-china/2482395/China-based ophthalmic pharmaceutical company Ocumension Therapeutics announced an agreement with Alcon under which OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon’s dry eye treatments and procedural drops, including establishe
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the
- ASCRS Launches Summit Designed to Enhance Refractive Cataract Surgery Practiceshttps://modernod.com/news/ascrs-launches-summit-designed-to-enhance-refractive-cataract-surgery-practices/2482384/In a move to enhance the adoption of advanced-technology IOLs (AT IOLs), the American Society of Cataract & Refractive Surgery (ASCRS) announced a new educational initiative—the ASCRS Business of Refractive Cataract Surgery Summit (BRiCS). The summit aims to equip practices with th
- Johnson & Johnson Invests in Refractive Technology Start-Up TECLenshttps://modernod.com/news/johnson-johnson-invests-in-refractive-technology-start-up-teclens/2482372/Johnson & Johnson closed a transaction to co-lead the Series A funding of TECLens, a start-up developing a nonincisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. Financial terms of the deal were not disclo
- New Data for Susvimo Demonstrates Sustained Efficacy in DME and DRhttps://modernod.com/news/new-data-for-susvimo-demonstrates-sustained-efficacy-in-dme-and-dr/2482365/Genentech and Roche announced 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively. Susvimo, which is being
- Latinos En Optometry Launches Redesigned Website and New Domain Namehttps://modernod.com/news/latinos-en-optometry-launches-redesigned-website-and-new-domain-name/2482291/Latinos en Optometry, a non-profit association dedicated to gaining a broader representation of Latinos and Spanish-speaking professionals within the optometry and larger eye care professional community, announced the launch of its redesigned website and new domain name,